Lentiviral Vector Optimization Service

Gene therapy has played an important role in a number of disease treatments, especially in various cancers. As a professional expert in lentiviral vectors, Creative Biolabs provides state-of-art technologies to meet any requirement of our customers. We have successfully completed a series of challenges in the past years. In particular, we have established an advanced lentiviral vector optimization platform which enables us to offer a series of high-quality service for the treatment of a collection of diseases.

Introduction of Lentiviral Vector in Gene Therapy

Gene therapy has been widely used in a number of disease treatment, such as tumors, as well as autoimmune diseases. In general, gene therapy is conducted by transferring therapeutic genes into specific cellular targets. These genes can recover the damages of gene variants, gene reprogramming, as well as defective cells, to improve the disease condition in animals or patients. For example, fusogenic membrane glycoprotein (GALV FMG) has shown its efficacy in cancer gene therapy. Pilot studies indicate that the lentivirus transfection system plays an important role in determining the efficacy of gene therapy.

In fact, gene transfer based on lentivirus has been proven its effectiveness, specificity, and stability for treating colon cancer, breast cancer, and diabetes. Meanwhile, three generations of the lentiviral vector have been identified based on the different packaged plasmids. The first generation consists of gag and pol sequences, several regulatory genes and accessory genes. Human immunodeficiency virus (HIV) related genes have been transferred into the former vector to generate the second-generation vector system. For the production of third-generation vector, genes, such as vif, vpr, vpu, and nef have been removed to enhance the safety of current vectors. In addition, recent studies have been focused on improving the functions of lentiviral vectors and a wide variety of methods have been established. Among them, glycoproteins, ligands, and promoters have become attractive targets for optimizing lentiviral vectors.

Manufacture of a lentiviral vector. Figure 1. Manufacture of a lentiviral vector. (Michael, 2018)

Service at Creative Biolabs

Gene therapy based on lentiviral vector has shown promising results in a range of disease therapy. Creative Biolabs now offers a large collection of lentiviral vector optimization services covering the entire lentiviral vector design, construction, safety assessment process, including but not limited to:

Recent studies have illustrated that glycoprotein represents great potential for treating a series of diseases, especially for cancer therapy. At Creative Biolabs, we provide pseudotyping services to expand the nature tropism and improve the stable expression of lentiviral vectors in a variety of cells. To date, we have developed many vectors targeting various cells, such as the central nervous cells, and lentiviral vectors have been pseudotyped using glycoproteins from the rabies virus.

Recently, our expert team has developed a ligand-retargeted platform for designing novel lentiviral vectors to improve the targeting specificity in numerous cell types. We have discovered a method for cell-specific targeting of lentiviral vectors by using the interaction of receptor-ligand proteins. For example, erythropoietin (Epo) protein has been fused to TVA or TVB receptors in our company. The data show that these ligand-receptor fusion proteins can trigger cell transduction to express specific Epo receptor (EpoR).

Scientists have theorized that the critical part of gene therapy against diseases requires suitable therapeutic vectors. Recent studies suggest that a number of lentiviral vectors, particularly for the tissue-specific lentiviral vector, should be perfect targets. Promoters have been generated and widely used for modifying lentiviral vectors to infect a variety of cells. For instance, we have designed two lentiviral vectors based on CD40L proximal promoter to treat X-linked hyper-immunoglobulin M syndrome (HIGM1) in animal models.

The lentiviral vector has been considered as a powerful gene delivery system because of the high transduction in nondividing cells. MicroRNAs (miRNAs) are small non-coding RNAs and often expressed in a number of tissue or cells, which indicates that miRNA is a key target for regulating cellular gene function. More recent studies conducted by our labs have proved that several artificial sites of microRNA can regulate the transgene expression of lentiviral vectors. In this condition, we provide the optimization services of lentiviral vectors based on miRNA. Our standardized protocol and rigorous quality control system enable us to provide perfect solutions for your project.

Bicistronic lentiviral vectors can deliver the stable expression of genes in disease therapy. This vector system is usually made up by ribosome entry site (IRES) elements, a furin cleavage site, and an amino acid spacer. It can regulate the expression level of T cell receptors (TCRs) in different types of lymphocytes. Currently, Creative Biolabs has developed a range of bicistronic lentiviral vector optimization services for our worldwide customers to identify proteins of interest by various detectable markers. In our assay, peptide tags and different 2A peptide linkers are widely used for increasing TCR expression.

As one of the top CROs in the field of lentiviral vector services, Creative Biolabs has focused on the development of gene therapies for years. We have accumulated extensive experience from the accomplishment projects and are very proud of our high-quality, omnidirectional lentiviral vector optimization services to meet any special need of your research. If you are interested in our services, please contact us or send us an inquiry.

Reference

  1. Michael, C.M.; et al. (2018). Clinical use of lentiviral vectors. Leukemia. 32: 1529-1541.
For research use only. Not intended for any clinical use.